India’s government has said that it has approved Gilead Sciences Inc’s antiviral drug remdesivir for emergency use for five doses in treating Covid-19 patients.

The approval comes a day after the US drugmaker reported that remdesivir showed modest benefit in patients with moderate Covid-19 given a five-day course, while those who received it for 10 days in the study did not fare as well.

Read full story here.